Quiver Bioscience is a technology-driven biotechnology company founded in 2013 that develops medicines for disorders of the brain, with a focus on central nervous system (CNS) conditions. The company is based in Cambridge, Massachusetts, and works at the intersection of genomics, perturbation biology, stem cell-derived human neuronal models, all-optical electrophysiology, artificial intelligence and machine learning.
Its core platform, the Genomic Positioning System (GPS), is described as a first-of-its-kind perturbation atlas of neuronal behaviour. The platform supports target identification, functional validation and safety assessment in drug discovery. The underlying experimental programmes have measured more than 9.6 billion action potentials across over 126 million neurons.
Quiver Bioscience's therapeutic pipeline covers CNS conditions including chronic pain, developmental and epileptic encephalopathies (DEEs), Dup15q syndrome, Fragile X syndrome and Tuberous Sclerosis. The company describes its approach as "empirical-in-a-loop", combining large-scale data generation with iterative analysis, and it collaborates with partners across pharma, biotech and government, including the NIH.
